PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Jan 24, 2020

byncaipen

Transplants

ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001 (AAGP®) molecule. We are...Read more

Jun 07, 2019

byncaipen

Transplants

ProtoKinetix Achieves Primary Objective Safety at Midpoint of Clinical Trial

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) today announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells used in conjunction...Read more

May 09, 2019

byncaipen

Transplants

Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has...Read more

Feb 26, 2019

byncaipen

Transplants

ProtoKinetix Releases Third in a Series of Scientific Update Videos

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the launch of the third in a series of informational videos by the Principal Investigators in each field currently...Read more

Dec 19, 2018

byncaipen

Transplants

ProtoKinetix Releases First in a Series of Scientific Update Videos

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the launch of the first in a series of informational videos by the Principal Investigators in each field currently...Read more

Sep 28, 2018

byncaipen

Transplants

ProtoKinetix Begins Cardiovascular Research

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences. Dr. Thomas...Read more

Sep 04, 2018

byncaipen

Ophthalmology | Transplants

ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company...Read more

Jan 10, 2018

byncaipen

Biomanufacturing | Transplants

ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP® on Monoclonal Antibody Production and Bone Marrow Recovery

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to announce that it has entered into a research agreement with The University of British Columbia (UBC), under...Read more

Oct 17, 2017

byncaipen

Biomanufacturing | Transplants

Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery

Belpre, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for the use...Read more

May 24, 2017

byncaipen

Ophthalmology | Transplants

ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP®

About ProtoKinetix, Incorporated ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.